INmune Bio received written alignment from the UK MHRA on its 2026 plan to seek conditional marketing authorization for CORDStrom™ (Ebstrocel™) to treat Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. MHRA agreed on the manufacturing, clinical, and non-clinical data requirements and recognized Phase 2 trial data showing meaningful symptom relief, especially for pain and itching, supporting its use as a chronic or intermittent therapy. The company is incorporating MHRA feedback into its Phase 3 trial design and aims to submit applications in the UK, EU, and US by late 2026 or early 2027. This regulatory milestone reduces risk and provides a clear path for potential approval of this novel cell therapy in an ultra-rare disease with limited treatment options.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Following a five-year antitrust lawsuit by Epic Games, Google will let Android users in the US download third-party apps directly from the Google Play Store starting July 22. This change comes after a court ruling that found Google's Play Store pract...
Ondo Global Markets reached $1 billion in total value locked (TVL) for tokenized stocks by May 2026, with projections to hit $5 billion by year-end. USDC, Circle's stablecoin, is the preferred settlement currency for these tokenized equities, favored...
